| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | William G. Kaelin | Q1603351 |
| P2860 | cites work | The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 |
| Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha | Q24308024 | ||
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2 | Q24684757 | ||
| Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth | Q24800550 | ||
| Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer | Q27824855 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages | Q28143066 | ||
| Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene | Q28202069 | ||
| Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation | Q28216594 | ||
| Molecular basis of the VHL hereditary cancer syndrome | Q28220414 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis | Q28236828 | ||
| Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein | Q28246139 | ||
| The concept of synthetic lethality in the context of anticancer therapy | Q28268061 | ||
| Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein | Q28269238 | ||
| Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha | Q28281963 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia | Q28300406 | ||
| HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption | Q28300415 | ||
| Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival | Q28352584 | ||
| Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice | Q28590550 | ||
| Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an ind | Q80445905 | ||
| Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension | Q81058982 | ||
| Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer | Q81311020 | ||
| Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment | Q83947086 | ||
| Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer | Q95807715 | ||
| Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor | Q36446896 | ||
| Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells | Q36528516 | ||
| Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression | Q36676341 | ||
| pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation | Q36731316 | ||
| Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. | Q36748085 | ||
| Role of primary cilia in the pathogenesis of polycystic kidney disease | Q36788907 | ||
| Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice | Q36953894 | ||
| Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen | Q36954859 | ||
| Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene | Q37285776 | ||
| Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor | Q40072900 | ||
| Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. | Q40127751 | ||
| pVHL and GSK3beta are components of a primary cilium-maintenance signalling network | Q40142798 | ||
| RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha | Q40179965 | ||
| Primary cilium formation requires von hippel-lindau gene function in renal-derived cells | Q40254089 | ||
| Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. | Q40296387 | ||
| Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor | Q40396846 | ||
| VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. | Q40479170 | ||
| Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. | Q40633683 | ||
| Tumour suppression by the human von Hippel-Lindau gene product | Q41320477 | ||
| Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha | Q43578303 | ||
| Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway | Q44019897 | ||
| Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein | Q44043145 | ||
| The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma | Q44043146 | ||
| HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron | Q44068443 | ||
| Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer | Q44071769 | ||
| Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin | Q44598505 | ||
| Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells | Q47639792 | ||
| A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma | Q48474924 | ||
| Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. | Q51803667 | ||
| Von Hippel-Lindau disease. | Q51971299 | ||
| p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. | Q52173333 | ||
| Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. | Q53381334 | ||
| Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. | Q54002922 | ||
| Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. | Q54279045 | ||
| Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway—A Report of the Tumour Angiogenesis Research Group | Q58211886 | ||
| Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein | Q80086881 | ||
| Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo | Q28594830 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| The primary cilium as the cell's antenna: signaling at a sensory organelle | Q29615165 | ||
| HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability | Q29615945 | ||
| Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway | Q29617805 | ||
| The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth | Q30480543 | ||
| Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. | Q33863055 | ||
| Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity | Q33925065 | ||
| Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. | Q33945016 | ||
| The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells | Q33959078 | ||
| VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling | Q33967117 | ||
| Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss | Q33984500 | ||
| Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. | Q34091273 | ||
| Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression | Q34104247 | ||
| Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma | Q34147530 | ||
| MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300 | Q34177495 | ||
| von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. | Q34514928 | ||
| Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha | Q34519869 | ||
| Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. | Q34530199 | ||
| Hsp90: a novel target for cancer therapy | Q34547609 | ||
| A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma | Q34553224 | ||
| Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. | Q34569182 | ||
| Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study | Q34584163 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal | Q34744818 | ||
| Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo | Q35065823 | ||
| The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells | Q35080738 | ||
| VEGF signalling: integration and multi-tasking in endothelial cell biology | Q35594143 | ||
| Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma | Q35621236 | ||
| The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo | Q35676249 | ||
| Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma | Q35741707 | ||
| Cystic kidney diseases: all roads lead to the cilium | Q35860406 | ||
| Role of VHL gene mutation in human cancer | Q35990141 | ||
| Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update | Q36066038 | ||
| The Akt-mTOR tango and its relevance to cancer | Q36260264 | ||
| P433 | issue | 10 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney cancer | Q3242950 |
| P304 | page(s) | 2262-2272 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein | |
| P478 | volume | 115 |
| Q37856382 | ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma |
| Q41252294 | Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI. |
| Q27676596 | Allosteric inhibition of hypoxia inducible factor-2 with small molecules |
| Q37724576 | Alterations in VHL as potential biomarkers in renal-cell carcinoma |
| Q38657787 | Axitinib in metastatic renal cell carcinoma: beyond the second-line setting |
| Q57021759 | CAIX and pax-8 Commonly Immunoreactive in Endolymphatic Sac Tumors: A Clinicopathologic Study of 26 Cases with Differential Considerations for Metastatic Renal Cell Carcinoma in von Hippel-Lindau Patients |
| Q35584182 | Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies |
| Q42705608 | Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma |
| Q39382008 | Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. |
| Q38303772 | Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma |
| Q35931293 | Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms |
| Q54338055 | Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney. |
| Q37109737 | Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α. |
| Q37701681 | EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor |
| Q35454927 | Emetine Promotes von Hippel-Lindau-Independent Degradation of Hypoxia-Inducible Factor-2α in Clear Cell Renal Carcinoma |
| Q27026023 | Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors |
| Q57578654 | First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response |
| Q39866397 | Genetic heterogeneity and chromatin modifiers in renal clear cell carcinoma |
| Q35971454 | Glycogen Synthesis is Induced in Hypoxia by the Hypoxia-Inducible Factor and Promotes Cancer Cell Survival |
| Q28075738 | Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy |
| Q92015559 | HNF‑4α downregulation promotes tumor migration and invasion by regulating E‑cadherin in renal cell carcinoma |
| Q35950501 | Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease |
| Q36646189 | Identification of biological targets of therapeutic intervention for clear cell renal cell carcinoma based on bioinformatics approach |
| Q35179504 | Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer |
| Q82153760 | JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma |
| Q37890209 | Kidney cancer pathology in the new context of targeted therapy |
| Q34589207 | Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN). |
| Q37017342 | Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials |
| Q38921098 | Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. |
| Q37078685 | MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells |
| Q39051696 | Minocycline accelerates hypoxia-inducible factor-1 alpha degradation and inhibits hypoxia-induced neovasculogenesis through prolyl hydroxylase, von Hippel-Lindau-dependent pathway. |
| Q38080737 | Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms |
| Q38299359 | Nucleoside diphosphate kinases (NDPKs) in animal development |
| Q37596123 | Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study |
| Q34072314 | Overcoming hypoxic-resistance of tumor cells to TRAIL-induced apoptosis through melatonin |
| Q37914865 | Oxygen sensing, homeostasis, and disease |
| Q35719850 | Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model |
| Q38179962 | Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity |
| Q58104118 | Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers |
| Q39067222 | Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity |
| Q54578238 | Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. |
| Q37301035 | Signaling hypoxia by hypoxia-inducible factor protein hydroxylases: a historical overview and future perspectives |
| Q37905587 | Targeted therapy in renal cancer |
| Q38074121 | Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors |
| Q38263008 | Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium |
| Q57949267 | Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial |
| Q38219283 | The role of HIF1α in renal cell carcinoma tumorigenesis. |
| Q38211079 | The role of inflammation in kidney cancer |
| Q37748477 | Treatment of metastatic renal cell carcinoma. |
| Q85849574 | Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases |
| Q37787564 | VHL Disease |
| Q33826897 | VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2. |
| Q35438578 | miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer |
| Q34299534 | microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion |
| Q34257789 | microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion |
| Q24622030 | von Hippel-Lindau disease: a clinical and scientific review |
| Q64074421 | von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME |
Search more.